22 studies found for:    scFv
Show Display Options
Rank Status Study
1 Completed IMCgp100 in Advanced Unresectable Melanoma
Conditions: Melanoma;   Advanced Disease;   Unresectable
Intervention: Drug: IMCgp100 injection
2 Completed Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha;   Drug: Placebo
3 Unknown  Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Multiple Myeloma;   Acute Myeloid Leukaemia;   Myelodysplastic Syndrome
Intervention: Biological: Anti-LeY- scFv-CD28-ζ vector,.
4 Completed Ocular Biodistribution Study for Topically Applied ESBA105
Condition: Cataract
Intervention: Drug: Placebo
5 Terminated Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gastric Cancer;   Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes;   Biological: aldesleukin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
6 Recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Conditions: Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
Intervention: Biological: DNA Vaccine
7 Recruiting CART-BCMA Cells for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-BCMA
8 Recruiting Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Drug: IMCgp100
9 Recruiting Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Conditions: Patients With B Cell ALL, Relapsed or Refractory, With no Available;   Curative Treatment Options (Such as Autologous or Allogeneic Stem Cell;   Transplantation) Who Have Limited Prognosis (> 12 Weeks Survival Expectancy);   With Currently Available Therapies.
Intervention: Biological: CART-19 cells
10 Completed Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
Condition: Anterior Uveitis
Intervention: Biological: ESBA105
11 Not yet recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Radiation: indium In 111-DOTA-biotin;   Radiation: yttrium Y 90 DOTA-biotin;   Drug: Clearing Agent;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
12 Completed A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
Condition: Advanced Solid Tumours
Intervention: Drug: L19IL2
13 Completed CART-19 for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-19 T cells
14 Recruiting CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Conditions: B Cell Lymphoma;   B Cell Leukemia
Intervention: Biological: Autologous 3rd generation CD19-targeting CAR T cells
15 Recruiting CART-meso Long-term Follow-up
Condition: Subjects Who Have Received Lentiviral-based CART-meso Therapy
Intervention: Biological: lentiviral-based CART meso therapy
16 Not yet recruiting Assessment of Toxicity of the Immunocytokine L19-IL2 Administered Directly After the Course of Stereotactic Ablative Body Radiotherapy in Patients Suffering From Oligometastatic Solid Tumour.
Condition: Solid Tumour
Intervention: Drug: L19-IL2
17 Recruiting D2C7 for Adult Patients With Recurrent Malignant Glioma
Conditions: Glioblastoma;   Glioma;   Malignant Glioma;   Brain Tumor, Recurrent
Intervention: Drug: D2C7-IT
18 Completed Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction;   Genetic: reverse transcriptase-polymerase chain reaction;   Biological: anti-CD19-CAR retroviral vector-transduced autologous T cells;   Biological: genetically engineered lymphocyte therapy
19 Not yet recruiting Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma
Condition: Malignant Melanoma
Interventions: Drug: IMCgp100;   Drug: durvalumab;   Drug: tremelimumab
20 Completed Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Condition: Malignant Melanoma
Interventions: Drug: rM28;   Drug: autologous PBMCs

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years